The US Centers for Disease Control and Prevention recently updated its science brief on COVID-19 vaccines currently authorized for emergency use (Pfizer-BioNTech, Moderna, and Johnson & Johnson), in which the agency synthesized the latest clinical trial data available through July 24, 2021. Data were added on vaccine efficacy and effectiveness against SARS-CoV-2 infection and SARS-CoV-2 variants, including the now dominant Delta variant. In the slides below, we summarize the key takeaways for primary care.
All 3 authorized vaccines (Pfizer, Moderna, and J&J) have been found effective against COVID-19, including serious outcomes of severe disease, hospitalization, and death.
Evidence suggests persons fully vaccinated with an mRNA vaccine are less likely than unvaccinated persons to acquire SARS-CoV-2 or to transmit it to others.
All currently authorized COVID-19 vaccines have demonstrated high efficacy against SARS-CoV-2 infection severe enough to require hospitalization and against COVID-19-associated mortality.
Preliminary data from clinical trials among adults aged ≥18 years suggest COVID-19 vaccination protects against symptomatic and may also protect against asymptomatic infection.
No studies have compared efficacy between any of the authorized COVID-19 vaccines in the same study population at the same time, making comparisons of efficacy difficult.